Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
CREB Activation by Mini-Chaperone Peptain-1-CPP (P1-CPP) Enhances Retinal Ganglion Cell Survival in an Acute Glaucoma Model
Author Affiliations & Notes
  • Gretchen Annika Johnson
    Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Raghu R Krishnamoorthy
    Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Ram H Nagaraj
    Ophthalmology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • Dorota Luiza Stankowska
    Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Gretchen Johnson None; Raghu Krishnamoorthy None; Ram Nagaraj Eyegenex Inc, Code O (Owner); Dorota Stankowska None
  • Footnotes
    Support  Gates Grubstake Fund (RHN)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1243. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gretchen Annika Johnson, Raghu R Krishnamoorthy, Ram H Nagaraj, Dorota Luiza Stankowska; CREB Activation by Mini-Chaperone Peptain-1-CPP (P1-CPP) Enhances Retinal Ganglion Cell Survival in an Acute Glaucoma Model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1243.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Our previous studies demonstrated that intravitreally injecting peptain-1, a peptide derived from αB-crystallin, can prevent the death of retinal ganglion cells (RGCs) in rats with ocular hypertension. Transcriptomics on RGCs of ocular hypertensive rats revealed cAMP response element-binding protein (CREB) signaling to be activated by peptain-1 conjugated with a cell-penetrating peptide (P1-CPP). This study investigated CREB phosphorylation (p-CREB) in rats with ocular hypertension following P1-CPP treatment.

Methods : Fifteen adult male Brown Norway rats were used, with five rats in each of three groups: naïve, IOP-Vehicle, and IOP-P1-CPP. To elevate intraocular pressure (IOP), 20µl of silicone oil was injected into the anterior chamber, followed by an intravitreal injection (2µl) of either PBS (Veh) or P1-CPP (2µg/µl). On the 7th day of elevated IOP, rats were euthanized, and their retinal sections were stained with anti-CREB, p-CREB antibodies, and DAPI. Retinal sections were imaged, and integrated density measurements were done. Statistical significance was calculated using unpaired t-tests or Mann-Whitney tests in GraphPad Prism. Finally, retinal punches from post-mortem human eyes were cultured with PBS or P1-CPP (12.5µg/ml) for 48 hours, and tissue RNA was collected for qPCR analysis.

Results : RGC counts in the IOP-Veh group revealed a 51% reduction compared to the naïve group (p<0.0001). The group that received P1-CPP after silicone oil injury (IOP-P1-CPP) exhibited a significantly lesser 23% decrease than the naïve group (p=0.0016). Assessment of integrated density for CREB expression in IOP-Veh showed a 17% increase (p=0.615) relative to the naïve group. In contrast, the IOP-P1-CPP group exhibited a substaintial 136% increase (p=0.092) compared to the naïve group. Analysis of p-CREB expression indicated a considerable 50% decrease in the IOP-Veh group compared to the naïve group (p=0.056). In contrast, the IOP-P1-CPP group displayed a significant increase compared to the IOP-Veh group (p=0.036). Lastly, RNA expression of Creb1 in human retinal tissue was increased by 1.7-fold with P1-CPP treatment compared to untreated tissue.

Conclusions : IOP-mediated damage to RGCs in rats was reduced by P1-CPP treatment via activation of CREB signaling. P1-CPP could be used as a neuroprotective agent for glaucoma.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×